The EULAR Study Group for Registers and Observational Drug Studies: Comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers

Rheumatology (United Kingdom)

Volumn 54, Issue 6, 2015, Pages 1074-1079

  Kearsley Fleet, Lianne ^a   Závada, Jakub ^b   Hetland, Merete Lund ^c,d   Nordström, Dan C ^e   Aaltonen, Kalle J ^f   Listing, Joachim ^g   Zink, Angela ^h   Gati, Tamas ⁱ   Rojkovich, Bernadette ⁱ   Iannone, Florenzo ^j   Gremese, Elisa ^k   van Riel, Piet L C M ^l   van de Laar, Martinus A F J ^m   Lie, Elisabeth ⁿ   Kvien, Tore K ⁿ   Canhão, Helena ^o,p   Fonseca, João E ^o,p   Rotar, Žiga ^q   Loza, Estibaliz ^r   Carmona, Loreto ^r   Askling, Johan ^s   Johansson, Kari ^s   Finckh, Axel ^t   Dixon, William G ^a   Hyrich, Kimme L ^a   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHARLES UNIVERSITY   (Czech Republic)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f UNIVERSITY OF HELSINKI   (Finland)

^g German Rheumatism Research Centre   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ SEMMELWEIS UNIVERSITY   (Hungary)

^j UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^k CATHOLIC UNIVERSITY   (Italy)

^l RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^m MEDISCH SPECTRUM TWENTE   (Netherlands)

ⁿ DIAKONHJEMMET HOSPITAL   (Norway)

^o UNIVERSITY OF LISBON   (Portugal)

^p HOSPITAL DE SANTA MARIA   (Portugal)

^q UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^r Institute for Health   (Spain)

^s KAROLINSKA INSTITUTE   (Sweden)

^t UNIVERSITY OF GENEVA   (Switzerland)

more..

Author keywords

Biologic therapies; Epidemiology; Outcome measures; Rheumatoid arthritis; Study design

Indexed keywords

IMMUNOGLOBULIN M; METHOTREXATE; PREDNISOLONE;

ADULT; AGE; ARTICLE; COMORBIDITY; CROSS-SECTIONAL STUDY; DAS28; DEPRESSION; DISEASE ACTIVITY; DISEASE DURATION; DISEASE REGISTRY; FEMALE; GENDER; HUMAN; HYPERTENSION; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SMOKING;

EID: 84938508745     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu446     Document Type: Article

References (20)

1. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68: 1136-45.
2. Mercer LK, Lunt M, Low AS et al. The risk of lymphoma in patients receiving anti-tumor necrosis factor therapy for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. Arthritis Rheum 2012;64(10 Suppl):S680.
3. Setoguchi S, Solomon DH, Weinblatt ME et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006;54: 2757-64.
4. Wolfe F, Michaud K. The effect of methotrexate and antitumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007;56: 1433-9.
5. Askling J, Baecklund E, Granath F et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009;68: 648-53.
6. Dreyer L, Mellemkjaer L, Andersen AR et al. Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides-a follow-up study from the DANBIO Registry. Ann Rheum Dis 2013;72:79-82.
7. Putrik P, Ramiro S, Kvien TK et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014;73:198-206.
8. Putrik P, Ramiro S, Kvien TK et al. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth? Ann Rheum Dis 2014;73:2010-11.
9. Galloway JB, Hyrich KL, Mercer LK et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011;50: 124-31.
10. Zink A, Manger B, Kaufmann J et al. Evaluation of the RABBIT Risk Score for serious infections. Ann Rheum Dis 2014;73:1673-6.
11. Atzeni F, Sarzi-Puttini P, Botsios C et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmunity Rev 2012;12:225-9.
12. Baecklund E, Iliadou A, Askling J et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
13. Hetland ML, Lindegaard HM, Hansen A et al. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry. Ann Rheum Dis 2008;67:1023-6.
14. Hyrich KL, Watson KD, Lunt M, Symmons DP. British Society for Rheumatology Biologics Register. Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008 Rheumatology 2011;50:117-23.
15. Hjardem E, Hetland ML, Ostergaard M et al. Prescription practice of biological drugs in rheumatoid arthritis during the first 3 years of post-marketing use in Denmark and Norway: criteria are becoming less stringent. Ann Rheum Dis 2005;64:1220-3.
16. Deighton C, Hyrich K. International guidelines on access to biologic therapy: why the differences and which is best? Nat Clin Pract Rheumatol 2008;4:520-1.
17. Deighton C, Hyrich K. Why do the French get much greater access to anti-TNF than the British? Vive la différence? Pas nécessairement. Rheumatology 2008;47: 1600-2.
18. Orlewska E, Ancuta I, Anic B et al. Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries. Med Sci Monit 2011;17: SR1-13.
19. Dixon WG, Carmona L, Finckh A et al. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis 2010;69:1596-602.
20. Radner H, Hyrich K, Dixon WG, Askling J. On behalf of EULAR Study Group for Registers and Observational Drug Studies. Consistency and usefulness of data items across European rheumatoid arthritis clinical cohorts and registers. Ann Rheum Dis 2014;73(Suppl 2):338.